Open AccessCyclophosphamide for Systemic Sclerosis-related Interstitial Lung Disease: A Comparison of Scleroderma Lung Study I and II
Author(s) -
Elizabeth R. Volkmann,
Donald P. Tashkin,
Myung Shin Sim,
Ning Li,
Dinesh Khanna,
Michael D. Roth,
Philip J. Clements,
AnnaMaria HoffmannVold,
Daniel E. Fürst,
Grace Kim,
Jonathan G. Goldin,
Robert M. Elashoff
Publication year - 2019
Publication title -
the journal of rheumatology/journal of rheumatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.577
H-Index - 178
eISSN - 1499-2752
pISSN - 0315-162X
DOI - 10.3899/jrheum.180441
Subject(s) - dlco , medicine , vital capacity , interstitial lung disease , placebo , scleroderma (fungus) , pulmonary function testing , cyclophosphamide , gastroenterology , diffusing capacity , lung , restrictive lung disease , spirometry , clinical endpoint , surgery , randomized controlled trial , lung function , chemotherapy , pathology , asthma , alternative medicine , inoculation
To compare safety and efficacy outcomes between the cyclophosphamide (CYC) arms of Scleroderma Lung Study (SLS) I and II.